Should You Buy Sensus Healthcare, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Sensus Healthcare, Inc. (SRTS) occupies a solid middle-ground position with a Quality of Company score of 7.3/10. At the current market price of $3.08, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 5 CirclFi valuation models project upside for Sensus Healthcare, Inc. (SRTS) at $3.08 — the model consensus leans bearish, with a Quality Score of 7.3/10 and Value-Trap risk of 32/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Sensus Healthcare, Inc. (SRTS) in 2026?
What Is the Bull Case vs the Bear Case for Sensus Healthcare, Inc. (SRTS)?
| Bull case — $3.76 target (+22.0%) | Bear case — $0.92 target (-70.0%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Sensus Healthcare, Inc.'s quality score of 7.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $0.92 (-70.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $3.76 (+22.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +92.1% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Sensus Healthcare, Inc.'s revenue and margin trajectory in the Medical Devices space. | Industry headwind: regulatory rejection risk represents a meaningful risk for Sensus Healthcare, Inc. and its Medical Devices peers. |
How Does SRTS Compare to Its Medical Devices Peers?
Valuation data pages: VREX · AORT · SNWV · SGHT · DCTH · LUNG · AHCO · IRIX · BWAY · IRMD · PODD
Which Other Stocks Score Like SRTS on Quality?
Closest companies to SRTS’s Quality of Company score of 7.3/10, across all industries.
- ADNT — Adient plc (QOC 7.3) · analysis
- HTGC — Hercules Capital, Inc. (QOC 7.3) · analysis
- RGCO — RGC Resources, Inc. (QOC 7.3) · analysis
- FMCC — Federal Home Loan Mortgage Corporation (QOC 7.3) · analysis
- SNOW — Snowflake Inc. (QOC 7.3) · analysis
- RYZ — Ryerson Holding Corporation (QOC 7.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does SRTS Appear In?
So Is Sensus Healthcare, Inc. (SRTS) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Sensus Healthcare, Inc. at $3.08. 4/5 models flag overvaluation, median fair value sits at $1.50 (-51.2%), and the risk-reward profile appears unfavorable. Quality at 7.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Sensus Healthcare, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About SRTS Stock?
Should I buy SRTS stock right now?
Based on CirclFi's multi-model analysis, 1 of 5 models see upside for SRTS at $3.08. The models are divided, which means the investment case depends heavily on your assumptions about Sensus Healthcare, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Sensus Healthcare, Inc.?
Key risks include: limited model coverage (5/13 active), reducing analytical confidence; wide model disagreement (307% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does SRTS compare to its competitors?
Among Medical Devices peers, SRTS holds a Quality Score of 7.3/10. Comparable companies include VREX (QOC 7.3), AORT (QOC 7.2), SNWV (QOC 7.4). The relative ranking helps investors identify whether SRTS offers better fundamental quality than alternatives in the same sector.
Is SRTS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SRTS's Quality Score of 7.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy SRTS at?
CirclFi does not provide target buy prices or price alerts. However, our 5 active models produce fair value estimates ranging from $0.92 to $3.76. At $3.08, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SRTS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad